Published Date: 16 Feb 2023
Many physicians have encountered one or more serious or potentially dangerous patients over the years, and according to Medscape research, patient trust has declined.
Read Full NewsThe history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.
US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.
Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.
Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.
A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.
Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.
1.
Use of marijuana and alcohol simultaneously is associated with worse outcomes.
2.
Measurable Residual Disease Predicts Real-World AML Relapse
3.
Alone for 500 Days, but Never Lonely: The Introvert's Dream.
4.
Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients
5.
For treatment, the majority of cancer patients choose complementary therapies.
1.
Analyzing the Mechanisms and Efficacy of Carboplatin, Abraxane, and Albumin-Bound Formulations
2.
A Visual Journey Through Penile Cancer: Examining the Impact of Photos
3.
Precision Medicine and Genomics: Harnessing Longitudinal Data Modeling to Decode Cancer Progression
4.
Understanding Acute Myeloid Leukemia (AML) and Its Survival Rates
5.
Revolutionizing Cancer Treatment: The Promise of Bevacizumab Injections
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
2.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
3.
Common Cancer Myths Debunked
4.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
5.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation